Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib

Kooybaran, Neda Rahbar; Petzold, Golo; Ströbel, Philipp; Schön, Michael P.; Mößner, Rotraut

doi:10.1111/ddg.14612

Cited by 20 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In OLP the use of JAKI is limited to case reports. Three OLP patients were successfully treated with JAKI, one of them with baricitinib and two others with upadacitinib ( 64 – 66 ).…”

Section: Janus Kinases Inhibitorsmentioning

confidence: 99%

Therapeutic strategies for oral lichen planus: State of the art and new insights

et al. 2022

View full text Add to dashboard Cite

Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa. Several clinical subtypes of OLP have been reported, including the reticular and erosive one. On the one hand, reticular OLP is usually asymptomatic and is characterized by white streaks surrounded by well-defined erythematous borders. On the other hand, erosive OLP shows ulcerations and erosions surrounded by erythematous mucosa. While reticular OLP is relatively easy to control, erosive OLP is extremely painful and refractory to therapies, limiting the quality of life of the patients. In addition, treating erosive OLP is extremely tricky, and a gold standard treatment has not yet been established. However, several therapeutic approaches have been reported as effective, including systemic corticosteroids, systemic retinoids, and anti-interleukin (IL)-17/anti-IL-23 drugs. Indeed, our group and other several authors reported the effectiveness of anti-IL17, anti-IL12/23, and anti-IL23 agents in refractory OLP, highlighting the urgency of clinical studies on the use of anti-IL agents in OLP patients. In this paper, we reviewed the English- and German-language literature about therapeutic strategies for treating OLP, focusing on new systemic therapies for erosive OLP.

show abstract

“…In OLP the use of JAKI is limited to case reports. Three OLP patients were successfully treated with JAKI, one of them with baricitinib and two others with upadacitinib ( 64 – 66 ).…”

Section: Janus Kinases Inhibitorsmentioning

confidence: 99%

Therapeutic strategies for oral lichen planus: State of the art and new insights

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The JAK inhibitors mentioned can be divided into two groups: baricitinib, delgocitinib, ruxolitinib and tofacitinib may be referred to as the alpha group of JAK inhibitors; these exhibit structural similarities and have a broader pharmacological binding selectivity than representatives of the beta group (abrocitinib, deucravacitinib, filgotinib, upadacitinib). Given the ubiquity of the JAK/STAT signaling pathway and its involvement in many regulatory mechanisms, especially in inflammatory processes, the use of various JAK inhibitors has been considered or already examined in clinical trials for many chronic inflammatory diseases involving the skin [44][45][46][47]. The most comprehensive data are available for indications of atopic dermatitis [38,48,49], psoriasis and psoriatic arthritis [34,50], alopecia areata [51][52][53], hand eczema [54] and vitiligo [55].…”

Section: Inhibitors Of Janus Kinasesmentioning

confidence: 99%

Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics

Eichner

Wohlrab

2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

The use of Janus kinase inhibitors for the treatment of chronic inflammatory diseases is increasingly establishing itself as a treatment option for several indications. In order to make clinical use efficient, pharmacological knowledge of the JAK/STAT signaling pathway and the special features of the pharmacokinetics of the individual drugs is essential. The JAK/STAT signaling pathway is regulated at several levels (receptor, kinase, STAT and SOCS levels), so when Janus kinase inhibitors are used, the clinically relevant pharmacodynamics are highly dependent on the dose regimen, treated indication, comedication and comorbidity. For all practical purposes, it is therefore of great importance to recognize that the factors mentioned above can have a relevant influence on the therapeutic benefit of the use of Janus kinase inhibitors. Against this background, it is particularly important to use the Janus kinase inhibitors in accordance with their approval.

show abstract

“…Case reports described good outcomes of LP under therapy with the JAK1/3 inhibitor tofacitinib [7][8][9]. Recently, a good therapeutic response of a patient with erosive oral and esophageal LP treated with upadacitinib, a preferential JAK1 inhibitor, was described [15], suggesting that not only the dual inhibition of JAK1 and JAK3, but also a predominant inhibition of JAK1 may be sufficient as therapy of oral LP. Clinical data on inhibition of JAK2 and TYK2 in patients with LP are to the best of our knowledge not available so far.…”

Section: Clinical Lettermentioning

confidence: 99%

Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib

Kooybaran

Petzold

Schön

et al. 2022

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib

Cited by 20 publications

References 11 publications

Therapeutic strategies for oral lichen planus: State of the art and new insights

Therapeutic strategies for oral lichen planus: State of the art and new insights

Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics

Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib

Contact Info

Product

Resources

About